chrisvoncsefalvay/vaers-outcomes huggingface dataset:
got first dose on 10Mar2021 and has not received the second yet/receive my second dose of the Moderna Covid-19 vaccine outside the recommended duration; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got first dose on 10Mar2021 and has not received the second yet/receive my second dose of the Moderna Covid-19 vaccine outside the recommended duration) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 023C21A and 001B21A) for COVID-19 vaccination.     Concomitant products included ATORVASTATIN, LISINOPRIL and OMEPRAZOLE for an unknown indication.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got first dose on 10Mar2021 and has not received the second yet/receive my second dose of the Moderna Covid-19 vaccine outside the recommended duration). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (got first dose on 10Mar2021 and has not received the second yet/receive my second dose of the Moderna Covid-19 vaccine outside the recommended duration) outcome was unknown.            No treatment information was provided.  Patient received his second dose of the Moderna Covid-19 vaccine outside the recommended duration i.e. after 83 days of the first dose. Patient mentioned he did not had any adverse effects after taking second dose   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Follow-up information received on29-JUN-2021 contains significant information. Details on second dose were added.
The second dose administered 38 days from the first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The second dose administered 38 days from the first dose) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016B21A and 028A21A) for COVID-19 vaccination.     Previously administered products included for Injury: tetanus on 23-Mar-2021.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 06-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The second dose administered 38 days from the first dose). On 06-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The second dose administered 38 days from the first dose) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications and treatment information were not provided.
Immediate local reaction to site.  After cleansing site with alcohol I gave shot.  At first it was "pea" sized reaction but within 5 min was large grape.  Denies itching or pain.
pt recvd Hep b vax on 5MAY92 & w/in 2 hrs following vax pt exp dizziness & vomiting;
This spontaneous report as received from a medical assistant refers to a 52 year old female patient. No information about medical history, drug reactions and allergies was specified. On 30-SEP-2014, the patient was vaccinated with temperature excursion supported PNEUMOVAX 23 injection (lot # K0045422, expiry date: 19-AUG-2015, dose 0.5 ml, intramuscular). No concomitant medications were reported. No adverse effects reported by patient. There was no product quality complaint. The outcome is unknown. This is one of the seven reports received from the same reporter (MARRS # 1410USA002854, 1410USA005576, 1410USA005584, 1410USA005585, 1410USA005586 and 1410USA005587). Additional information has been requested.
Patient had no adverse effects or symptoms from receiving this dose; an adult patient received a 0.5 ml dose of VAQTA rather than the 1 ml dose; This spontaneous report was received from a nurse referring to a 19 year old patient of unknown gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported.   On 07-JUN-2022, the patient received a 0.5 ml dose of hepatitis a vaccine, inactivated (VAQTA) rather than the 1 ml dose (lot number U033212 with expiration date 07-NOV-2022) (inappropriate dose of vaccine administered). The patient had no adverse effects or symptoms from receiving this dose.
Swollen lymph node on the side of the neck, arm pain and shoulder pain for the last 6 weeks, chest pain, shortness of breath, inflamation of chest and upper pericardium, left arm swelling, tingling in left hand.
Initial report received on 09/Mar/2006 from a health care provider. A 46 year old female patient with a history of hypertension, had received an intramuscular injection of Decavac, lot number U1617GA (corrected), in the left deltoid on 17/Jan/2006. Thirty-one days later, she developed muscle aches, stiffness and limited range of motion in the left arm that lasted five weeks. An MRI was completed (results not reported). At the time of this report the patient had not recovered from these events. Follow-up information received on 07/Apr/2006 from responsible physician. The patient had no illness at the time of vaccination. It was confirmed by the reporter that the injection was administered in the left deltoid. The patient had an MRI (date performed not reported) which showed tendonosis, tendonpathy, bursitis and residual red marrow infiltration. Per responsible physician, the patient was 70% better on 10/Mar/2006. Follow-up information received on 15/May/2006 from responsible physician. Per reporter the patient had no past history of tendonpathy or tendonitis. Decavac was received as a booster. The MRI was performed on 10/Mar/2006 and showed 1. Mild supraspinatus tendinopathy with some mild subdeltoid bursitis. 2. Mild hypertrophic changes of the AC joint. 3. Probably residual red marrow in the proximal humerus. Per reporter the presumed mechanisms are unclear. The physician did not consider the bursitis to be caused by vaccine misadministration into the bursa. Recovery status of the patient was not reported. No further information expected. Additional documents available with source files: MRI result.
Patient was given Hepatitis A, VZV, MENACTRA. Upon administration of VZV (3rd shot as Hep A & MENACTRA given 1st) patient had vasovagal episode < 10 seconds and recovered in prone position. No further complications.
Pt reports same symptoms she had with Covid exposure in October. Fever, chills, body aches, weakness, loss of appetite,  difficulty breathing.
Loss of taste. I can still smell ok, but I can not taste foods, such as sweet, salt spicy, bitter, etc.
burning pain on underside of left arm from elbow to 4 inches up arm.  no redness some swelling.  started day after vaccine and is still on going 8 days later.  my husband also had the same side effect but his only lasted 4 days
Pain in arm where injection was given.  Pain felt for about two days, then went away, then came back.  Pain enough to affect range of motion and hurts to raise arm and to dress.  It's an ongoing ache.  Aleve helped to reduce pain but it has not gone away. Will need to see my primary physician about it.
Pt received bivalent booster on 11/3/22. Called hospital call ceneter on 11/8/22 to report diarrhea since 11/5/22. Tried antidiarrheals but has not helped.  Pt denies any changes to diet. Pt recommended by RN to go to urgent care or see PCP for further evaluation.
Sunday afternoon discovered painful swollen lymph node in left armpit with pain radiating to left breast. Had mammogram in December and results were negative for breast cancer, but it was scary to feel the sensation in my breast.
Pt recvd 2nd dose of vax & felt numbness on whole lt side; cheek, lt arm & lt leg were weak;
right side of her face was swollen and was itching; eyes swollen/puffy; puffy underneath eyes/ like bags; swelling of right side of face/ right side of her face was swollen; This is a spontaneous report from a contactable consumer (patient). A 71-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE lot number: EL1284, expiration date: 30Apr2021) intramuscular on the right arm on 15Jan2021 at 30 ug, single for COVID-19 prophylaxis. Medical history included high cholesterol, high blood pressure, cancer survivor and allergic to walnuts. Concomitant medication included ascorbic acid, herbal nos, levoglutamide, lysine, magnesium, manganese, retinol, riboflavin, selenium, tocopherol, zinc (AIRBORNE) for supplementation therapy, HCTZ for high blood pressure, vitamins nos (MULTIVITAMIN [VITAMINS NOS]) for supplementation therapy, rosuvastatin for high cholesterol. The patient received 1st dose of vaccine on Friday and on 17Jan2021 evening, experienced the following: "swelling of right side of face, eyes swollen/puffy." She spoke with HCP office and was told to take Benadryl and Tylenol. She took the medication and the "swelling went down". She said she woke up this morning and had "puffy underneath eyes", "like bags", and "slight facial swelling." The patient ate at an Indian restaurant on 17Jan2021 at about 6:30-7:00pm and was unsure if her reaction was to the vaccine or food, since the food she ate could have been cooked with nut oil. She said that her eyes were still puffy and her face was still a little swollen. She went to see her doctor today 19Jan2021 and he was trying to figure out what could have caused this on his end. The patient said that the right side of her face was swollen and was itching. The left side did not appear to be swollen at all. Outcome of the event pruritus facial was unknown while recovering for the other events.
PROQUAD and VARIVAX were administered on the same day to an adult patient instead of VARIVAX and MMR II; PROQUAD and VARIVAX were administered on the same day to an adult patient instead of VARIVAX and MMR II; This spontaneous report has been received from a nurse referring to a 47-year-old male patient. Information about pertinent medical history, concomitant medication or drug reactions/allergies was not provided.  On 08-OCT-2020, the patient was administered with measles, mumps, rubella and varicella (Oka-Merck) virus vaccine live (PROQUAD) 0.5 milliliter, lot # S038146, expiration date 25-MAY-2021 (strength and route were not reported) (inappropriate age at vaccine administration) and varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 milliliter, lot # S019463, expiration date 24-JUN-2021 (strength and route were not reported) for prophylaxis, instead of varicella virus vaccine live (Oka/Merck) (VARIVAX) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (wrong vaccine administered). The outcome of the events and the action taken with suspect therapies was not reported.
Left facial myoclonus, erratic pattern multiple times throughout the day lasting 7-9 seconds .
After about 10 minutes of the injection, patient came to the pharmacy window stating "I  can't breath. I can't breath". We settled patient down on chair. Patient also c/o tongue tingling, heart racing, and dizziness. After assessment, pt was given 1 dose of EpiPen. We called 911 and patient was transported to ER for further evaluation.
Physician reported that patient received vaccination on 10/19/00 and that same day developed a fever "up to 105 deg. F". She was treated with Tylenol (acetaminophen).
Patient received vaccine on 3-4-15 due to hospital employee policy change. Patient had titers drawn and were negative. Patient woke up in the middle of the night of 3-11-15 with right jaw pain and swelling. Patient was seen at medical clinic on 3-12-15. Trimethoprim 100mg was given to patient. Patient was required to stay home from work due to working in a health care facility. Patient was then seen again on 3-14-15 to follow up. At that time, the patient's symptoms had resolved.
Pain in back, legs, shoulder and neck with ascending neurological symptoms, hypothesized as Guillain-Barre Syndrome. Still undergoing tests and physical therapy.
acutely arthritic hands and wrists with swelling, redness, warmth and significant pain and reduced mobility; mild headache; mild injection site reaction/local site reaction (redness); A spontaneous report was received from a retired physician, who was also the husband of a 57 year old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced mild headache, mild injection site reaction/local site reaction (redness)/injection site erythema, and arthritic hands and wrists with swelling, redness, warmth and significant pain and reduced mobility/arthritis.  The patient's medical history included gastroesophageal reflux disease. The patient had ongoing condition of multiple sclerosis. The concomitant medications included  interferon beta-1a, esomeprazole magnesium, and escitalopram.  On 16 Feb 2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 031M20A) intramuscularly  in left arm for prophylaxis of COVID-19 infection.   The patient had experienced mild headache for first 12 hours post vaccination, local site reaction (redness) for 5 days after vaccination.   On 25 Feb 2021, the patient experienced acute wrist, metacarpophalangeal, proximal interphalangeal and distal interphalangeal joint pain with swelling, reduced range of motion, redness and warmth in both hands though it started first in left hand. The patient was unable to pick glass of water due to significant pain which worsened in the morning gradually improving throughout the day.  The reporter felt this event was disabling for the patient.  Treatment information was not provided.  Action taken with mRNA-1273 was unknown.  The events of mild headache and mild injection site reaction/local site reaction (redness) were resolved.  The event of arthritic hands and wrists with swelling, redness, warmth and significant pain and reduced mobility was not resolved at the time of this report.; Reporter's Comments: This case concerns a 57 year old, female patient, who experienced serious event of acute arthritis and non serious events of headache and vaccination site erythema. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.  Further information has been requested.
The morning after I received my booster shot my arm at the injection site was very swollen and red and hot to the touch also extremely painful.
Patient was nervous about getting a covid shot so decided to get the Janssen as it was one shot and more like the flu shot, I gave him the vaccine in his right deltoid and he had some blood drip which I cleaned up after putting on cotton ball with bandage as I was cleaning up and talking to him he got pale and passed out in the chair. I called to someone to call 911 as he i was getting him lowered, I removed his mask to help with breathing, and hugged him to lower him to the ground, while I was lowering him he came too and kicked as he was startled. I laid him on the ground in imz booth and had someone get my garden pad I keep in the pharmacy to place under his head. I had someone get him damp paper towel  for his forehead. The floor was cool on his back which helped cool him down. The color came back to his face and  He said he felt fine but was embarrassed which we reassured him it was all good. He said he felt more awake then when he came in. The ambulance arrived and he stood up and he was fine and didn't go with them. I gave him a vial of water and thanked us and went on his way.
This spontaneous report as received from a pharmacist refers to a male patient of unknown age. On approximately 19-SEP-2013, reported as "a week ago" the patient was vaccinated with a dose of ZOSTAVAX (lot number reported as J0004268, expiration date: 12-JUL-2014, dose and route not reported). On an unspecified date in September 2013, after receiving ZOSTAVAX the patient developed rash. On an unknown date in September 2013 the rash subsided and the patient recovered fully with no issue. This is one of two reports received from the same source (related MARRS # 1309USA013337, concerns the patient female friend who also developed rash after the same lot of ZOSTAVAX). Additional information has been requested.
full body rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (full body rash) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (full body rash). At the time of the report, RASH (full body rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Treatment medication includes: Steroids
Fever, chills, nausea, vomiting, profuse sweating, malaise
11 y.o. Male received dose of Pfizer COVID-19 (12+) Vaccine. No s/s of adverse reactions noted or reported by patient and parents to date.
patient was not yet 18 years old.  he will be 18 when his 2nd dose is indicated.  no issues to report other than sore arm and back.
One day after vaccine, injection site became red, swollen, hot to the touch. There was also a hard lump. Patient seen in this office today. Arm better, but still swollen, red, & hot to the touch. Patient put on Benadryl, 1 1/2 tsp. q 6 hours. Patient to return tomorrow for follow-up.
Pt recvd vax & 1 hr later exp flushing, dizziness, erythema, & sweating; sx resolved p/30 minutes; No further details are available;
Severe fatigue; headache; chills; hot flashes; This is a spontaneous report from a non-contactable other healthcare professional. A 31-year-old (age at the time of vaccination was 31-year-old) male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EL3247), via intramuscular route of administration on 03Feb2021 12:00 PM at single dose in right arm for COVID-19 immunisation at clinic. The patient medical history and concomitant medications were not reported. It was reported that the patient had not received COVID prior vaccination. The patient experienced severe fatigue onset 24 after receiving shot on 04Feb2021; duration 48 hours. Included headache, chills, and hot flashes on 04Feb2021. Treatment was not received for adverse events. No other vaccine in four weeks. The patient was not tested for COVID post vaccination. The outcome of all events was recovering.  No follow-up attempts are possible. No further information is expected.
Within a few days after first dose, my blood pressure went up. Normally I am borderline high (135/80). I have a family history, so I take my BP at home. Over the next few days, it continued to climb. On Sunday night, two weeks after the vaccine, I got a terrible headache and visual disturbance. I took my BP and it went up to 220/120. I thought I was having a stroke, but it turned out to be an ocular migraine. I had only one migraine in my life. It was a month after a TBI, 2 years ago. This was much worse, though, and they are continuing. My BP would not go down, so the doctor has me on BP meds, which I also never needed previously. Despite the meds keeping the BP controlled, I am getting ocular migraines almost daily. It spiked again after the 2nd vaccine dose. The ocular migraines became almost daily following the 2nd one. Two pharmacists told me they are hearing this quite frequently (about the BP and the ocular migraines). The migraines in general, even with those who have never had them previously. I posted online, "I got the COVID vaccine," because I was initially excited to get it. When this happened, I posted about the extremely elevated BP and ocular migraines. Many posted about having had similar reactions. I hope they are reporting these things here!
Uncertain of anything right after vaccine. Admitted to hospital with hyponatremia and alcohol abuse.   Was dx with COVID after admitted to hospital during this admit.
I had a delayed cumulative reaction and I contacted my physician who was concerned pulmonary embolism. Diagnosis with leaky blood vessel. I saw a cardiologist and pulmonologist who scheduled test through the Hospital-categorized as outpatient surgery. Due to vaccination was mandated and the job indicated that they would compensate for issues with the vaccination. Had a head to toe physician the day prior to the 12/28/2020 vaccination of Dose 1 12/29/2020.
Fever of 102.3, severe body and muscle aches aches, throat pain, chills, confusion, headache, fatigue
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose :04/12/21pfizer,Lot# EW0150 2nd dose: 05/05/21,Pfizer,Lot# ER8736 Diagnosed covid positive:07/16/2021 Exposure:Travel Symptoms:SOB, cough,fatigue,muscle ache,chills, fever. sore throat.
Patient received vaccine on 8/23/22. On 8/25/22 patient developed changes in vision including a flash in their left lateral eye worsening to area of vision being slightly off center and a gray/white flashing spot that is like a curtain over field of vision. Patient had an emergent office visit and was initially diagnosed with ocular migraine related to SSRI they are taking. Patient was then seen by a retina specialist and was diagnosed with Multiple Evanescent White Dot Syndrome.
Presentation 9th day status post immunization with generalized macular-papular rash on trunk and compaints of generalized fatigue.
edema of my feet, ankles, up to both knees; edematous areas red coloured; edematous areas feel hard; This case was reported by a consumer via call center representative and described the occurrence of peripheral edema in a patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included mastectomy (had 1 year before the reporting date, 10 nodes were removed, 2 were positive) and axillary lymphadenectomy. Concomitant products included tramadol.   On 17th April 2019, the patient received the 2nd dose of Shingrix (intramuscular). On 18th April 2019, 1 days after receiving Shingrix, the patient experienced peripheral edema, erythema edematous and skin induration. On an unknown date, the outcome of the peripheral edema, erythema edematous and skin induration were unknown.   It was unknown if the reporter considered the peripheral edema, erythema edematous and skin induration to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient noticed who had edema in both of feet, ankles, up to both knees.  The edematous areas felt hard, not pitted, and red colored.  The only new medicine the patient received late Friday from patients radiation oncologist was tramadol 50 mg, 1 tab Q 4 hours as need.
POSITIVE COVID TEST; This spontaneous report received from a patient via a company representative concerned a 59 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 01-NOV-2021, the patient experienced positive covid test. Laboratory data (dates unspecified) included: SARS-CoV-2 test (NR: not provided) Positive. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of positive covid test was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comment not required as per standard procedure as the case is assessed as non serious.